Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

AGuIX

François Lux1,2, Vu Long Tran2,3, Eloïse Thomas2

  • 1NH TherAguix SAS, Villeurbanne, France.

The British Journal of Radiology
|September 19, 2018
PubMed

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Targeted delivery of proteolysis-targeting chimeras (PROTAC) and molecular glue degraders (MGD).

Advanced drug delivery reviews·2026
Same author

Artificial Intelligence Decodes Brain Elemental Signatures to Stratify Aging and Neurological Diseases.

Research (Washington, D.C.)·2026
Same author

Engineering the subcutaneous delivery of antibody-drug conjugates.

Journal of controlled release : official journal of the Controlled Release Society·2026
Same author

Inverse Correlation between Endoplasmic Reticulum Stress Intensity and Antitumor Immune Response with Ruthenium(II)-Based Photosensitizers for the Photodynamic Therapy of Head and Neck Squamous Cell Carcinoma.

Journal of medicinal chemistry·2025
Same author

A Modular Supramolecular Peptide Platform Reveals Atomic-Number-Dependent Mechanisms Driving Radioenhancement.

ACS nano·2025
Same author

Nanomaterials Trigger Functional Anti-Tumoral Responses in Primary Human Immune Cells.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)·2025
Same journal

Ensuring radiology reporting quality across a national lung cancer screening programme.

The British journal of radiology·2026
Same journal

Utility of High-Resolution Semiconductor Positron Emission Tomography/Computed Tomography in the Assessment of Breast Cancer Extent: Comparison with Magnetic Resonance Imaging.

The British journal of radiology·2026
Same journal

Airway Imaging Practices in Primary Ciliary Dyskinesia: A Global Survey to Guide Standardized Guidelines.

The British journal of radiology·2026
Same journal

Letter to the editor: A comment on statistical power in high-dose radiation group analysis.

The British journal of radiology·2026
Same journal

"Comparative diagnostic accuracy of dual-energy CT, diffusion-weighted MRI and chemical shift MRI in cervical lymph node metastasis in head and neck cancer".

The British journal of radiology·2026
Same journal

The Utility of Advanced Imaging in COPD: Diagnosis, Prognosis, and Treatment-introductory Editorial.

The British journal of radiology·2026
See all related articles
Summary
This summary is machine-generated.

AGuIX nanoparticles, a novel gadolinium-based radiosensitizer, show no toxicity and effectively enhance radiotherapy in preclinical models. Clinical trials are underway, demonstrating promising results for various cancer types.

Area of Science:

  • Nanomedicine and Radiotherapy
  • Preclinical Cancer Research
  • Nanoparticle Drug Delivery

Background:

  • AGuIX® are sub-5 nm gadolinium chelate nanoparticles within a polysiloxane matrix.
  • These nanoparticles are entering clinical trials for use with radiotherapy.
  • Preclinical data supports their potential as a radiosensitizing agent.

Purpose of the Study:

  • To review the preclinical findings supporting the clinical use of AGuIX nanoparticles.
  • To assess the safety and efficacy of AGuIX in various cancer models.
  • To provide an overview of the second-generation AGuIX nanoparticles and early human results.

Main Methods:

  • Review of preclinical studies including toxicity tests and biodistribution analyses in animal models.
  • In vitro and in vivo studies evaluating the radiosensitizing effects across diverse cancer types.

Related Experiment Videos

  • Analysis of data leading to first-in-human administration.

    • Main Results:

    • No toxicity observed in regulatory tests on rodents and monkeys.
    • Demonstrated passive tumor uptake via EPR effect and renal clearance post-IV administration.
    • Significant radiosensitizing effects observed in vitro and in vivo for brain, lung, melanoma, and head and neck cancers.

    Conclusions:

    • AGuIX nanoparticles exhibit a favorable safety profile and potent radiosensitizing capabilities.
    • Preclinical success has translated to early-stage human clinical trials.
    • Ongoing research includes second-generation nanoparticles and preliminary human outcomes.